secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001628280-26-024061
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Collegium nominates Michael Donovan for board; director John Fallon to retire
-----------------------------------------------------------------------------

- Michael Donovan, 60, audit partner at EY since 2002, nominated to stand for election at 2026 annual meeting.
- John Fallon, M.D., will not stand for re-election and will retire from the board effective as of the annual meeting.
- Dr. Fallon served as director since 2016; his retirement is part of board refreshment and succession planning, not due to any disagreement.
- Mr. Donovan brings financial expertise from 36 years of experience in life sciences audits and transactions (IPOs, M&A, collaborations).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000162828026024061/0001628280-26-024061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000162828026024061/coll-20260402.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-024061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer